Display of DNA on Nanoparticles for Targeting Antigen Presenting Cells

Area of Science:

• Nanotechnology
• Immunology
• Vaccine Development

Background:

• Efficient antigen delivery is crucial for effective immunotherapies and vaccine development.
• Targeting antigen-presenting cells (APCs) is a key strategy to enhance immune responses.
• Current nanoparticle delivery systems face challenges in optimizing APC uptake and biodistribution.

Purpose of the Study:

• To investigate the efficacy of conjugating CpG oligonucleotides to E2 protein nanoparticles for improved APC targeting.
• To evaluate the impact of oligonucleotide display on nanoparticle uptake and retention in vitro and in vivo.
• To assess the potential of this approach in overcoming delivery barriers for vaccine development.

Main Methods:

• Conjugation of CpG oligonucleotides to an E2 protein nanoparticle surface, creating CpG-PEG-E2 nanoparticles.
• In vitro assessment of APC uptake comparing CpG-PEG-E2, non-CpG DNA-E2, and E2-alone nanoparticles.
• In vivo evaluation of lymph node retention and APC uptake of CpG-PEG-E2 nanoparticles compared to controls.

Main Results:

• CpG-PEG-E2 nanoparticles demonstrated approximately a 4-fold increase in in vitro APC uptake compared to E2 alone.
• In vivo studies showed enhanced lymph node retention for CpG-PEG-E2 up to 48 hours.
• A 2-fold increase in in vivo APC uptake was observed with CpG-PEG-E2 compared to E2-alone or PEGylated E2 nanoparticles.

Conclusions:

• Oligonucleotide display on nanoparticle surfaces enhances APC uptake and improves pharmacokinetic properties.
• CpG-PEG-E2 nanoparticles show significant potential for improving antigen delivery in vaccine development.
• This strategy may help overcome critical delivery barriers, leading to more successful vaccines.